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Summary The radiolabelled opioid receptor binding affinities of morphine and its active metabolite morphine
6-glucuronide at the total mu, mu 1, mu 2 and delta receptors were determined. Morphine 6-glucuronide was
found to have a 4-fold lower affinity for the mu 2 receptor (IC50 17 nm and 82 nm for morphine and morphine
6-glucuronide respectively, P = 0.01), the receptor postulated to be responsible for mediating the respiratory
depression and gastrointestinal effects after morphine. This provides a possible explanation for the reduced
respiratory depression and vomiting seen following morphine 6-glucuronide in man. A similar reduction in
affinity of morphine 6-glucuronide was seen at the total mu receptor whilst there was no significant difference
seen at the mu or delta receptor. Hence the increased analgesic potency of morphine 6-glucuronide over
morphine remains unexplained.
Morphine is one of the commonest drugs prescribed by
cancer physicians and is an effective potent analgesic. How-
ever one or more of the side effects of constipation, nausea
and vomiting, and sedation are encountered frequently (Jaffe
& Martin, 1991). Respiratory depression is a less common
problem but is the most potentially dangerous toxicity. An
analgesic with equivalent potency but lower toxicity would
therefore be of particular use.
The major metabolic products of morphine are morphine
3-glucuronide (M3G) and morphine 6-glucuronide (M6G).
Although M3G is devoid of analgesic activity, M6G is now
thought to play a major role in mediating the analgesic effect
of morphine (Osborne et al., 1986; Hanks et al., 1987; Hos-
kin & Hanks, 1990). When given directly M6G has been
demonstrated to have more potent antinociceptive activity
than morphine in animals (Shimomura et al., 1971; Pasternak
et al., 1987; Abbott & Palmour, 1988; Paul et al., 1989). It is
tempting to presume the receptor binding profile ofmorphine
and M6G is similar with M6G purely binding more avidly to
the same receptors as morphine. However there are now
several pieces of biochemical and clinical evidence to suggest
this is not the case. Shimomum et al. (1971) found the
systemic LD50 of M6G to be 88% that of morphine and
hence first suggested the lethal effects of M6G did not
directly correlate with its analgesic potency advantage over
morphine. In addition glucuronidation is normally a natural
mechanism of the body to detoxify noxious substances.
An open study in man (Osborne et al., 1989) provided
anecdotal evidence in man that M6G may have a better
toxicity profile than morphine as no nausea or sedation was
seen at doses sufficient to give significant pain relief. A recent
double-blind randomised study comparing the respiratory
depression induced by equipotent doses of morphine and
M6G in normal volunteers (Thompson et al., 1990) demon-
strated that significantly less respiratory depression was
caused by M6G. In addition less nausea and no sedation was
again observed.
The apparent improved therapeutic /toxic ratio of M6G
over morphine suggests these compounds have different
opioid receptor binding profiles. From a number of studies
the existence of several types of opioid receptor has been
proposed (Gilbert & Martin, 1976; Lord et al., 1977; Wuster
et al., 1979; Wolozin et al., 1981; Pasternak et al., 1980.
Gouarderes et al., 1981; Rothman & Westfall, 1982), but
there remains controversy over the existence and the func-
tional and structural relationships of the various opioid
receptor subtypes, particularly of the mu and delta receptor.
Despite this, recent developments in producing selective
enkephalin agonists has enabled the comparative affinity of
different compounds to individual types of receptor to be
determined via radioligand binding studies.
For the purpose of the current study we have chosen the
model proposed first by Pasternak and colleagues (Wolozin
& Pasternak, 1981). This model suggests there is a common
receptor labelled by either a prototypic delta agonist such as
DADLE (D-Ala2, D-Leu5-enkephalin) or with a mu agonist
such as morphine which has high affinity for morphine. This
they termed the mu 1 receptor. The receptor labelled with a
mu agonist which possessed a lower affinity they termed the
mu 2 receptor. Similarly the receptor labelled with a delta
agonist possessing lower affinity for morphine they termed
the true delta receptor.
It has been postulated that several of the adverse affects
including respiratory depression of morphine are due to
activation of the mu 2 or lower affinity mu opioid receptor
(Pasternak & Wood, 1986). Using this classification it was
therefore hypothesised that M6G has a lower affinity for the
mu 2 receptor than morphine at least partially explaining the
lower apparent toxicity seen in man. The aim of the current
study was to investigate this hypothesis by comparing the
receptor affinities of the two compounds by the use of
radiolabelled binding studies on homogenised rat brain pre-
parations.
Materials and methods
In this study the method ofYoburn et al. (1988) was adapted
to provide binding affinities, as expressed by the IC50, of
morphine and M6G at each of the mu 1, mu 2, total mu and
delta receptors. The IC50 is defined as the concentration of
morphine or M6G to displace 50% of the 3H-ligand
specifically bound to the opioid receptor subtype.
Tissuepreparation
Binding studies were performed using homogenised brain
(minus the hypothalami used by other investigators) prepara-
tions from Wistar rats weighing 200-300 g. The rats were
decapitated, the brains removed and hypothalami dissected
out, before being washed in ice-cold 10 mM Tris HCI (pH 7.4
at room temperature), damped dry and weighed. The brains
were then minced with scissors and homogenised in 4 x w/v
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ice-cold 10 mM HCl containing 0.32 M sucrose (Goldstein et
al., 1971) using an Ultra Turrex tissue homogeniser (Janke
and Kankel Ltd). The homogenates were kept standing on
ice throughout the procedure. Homogenates were centrifuged
at 1000 g for Omin at 4°C to remove the crude nuclear
pellet. The supernatant was removed and recentrifuged at
100,000 g for 90 min at 4°C. The supernatant was removed
and the pellet (P2) resuspended in a minimal volume of
10 mM Tris HCl buffer. An estimation of the protein concen-
tration was made by using a modified Lowry protein assay
(Boerhinger Mannheim, Mk78). The P2 suspension was then
diluted with-buffer to achieve a final protein concentration of
4 mg ml -. The P2 fractions were aliquoted and stored at
- 3OC for up to 3 weeks.
Peptides
DAGO, DSLET and DPDPE were obtained from Peninsula
laboratories and 3H-DAGO and 3H-DSLET from Du Pont
(UK) Ltd. Morphine sulphate was obtained from McCarthy
Medical Ltd, UK, and M6G from Ultrafine Chemicals Ltd,
UK.
Assay procedure
The list of synthetic enkephalin ligands used with their
assumed receptor specifities is displayed in Table I. All assays
for specific binding were performed in triplicate in 10 ml
plastic test tubes and assays for total binding and non-
specific binding performed in quadruplicate using the follow-
ing experimental procedure:
Total bindings (i) 0.5 ml P2 (4 mg ml-').
(ii) 0.1 ml 3H-DSLET (1.5 nM) (mu 1 and del-
ta assays) or 0.1 ml 3H-DAGO (1.5 nM) (total mu and mu 2
assays).
(iii) 0.1 ml Tris-HCl buffer (pH 7.4 at room
temperature).
Vortex and pre-incubate in shaking water bath at 37°C for 5 min.
(iv) 0.1 ml Tris-HCl buffer.
Vortex and incubate in shaking water bath at 37°C for a further
15 min.
Non-specific binding (i) 0.5ml P2 (4mgml-').
(ii) 0.1 ml 3H-DSLET (1.5 nM) (mu 1
and delta assays) or 0.1 ml 3H-DAGO (1.5 nM) (for total mu
and mu 2 assays).
(iii) 0.1 ml DPDPE (20 nM) (mu 1 as-
say), 0.1 ml DSLET (5 nM) (mu 2 assay), 0.1 ml DAGO
(5 nM) (delta assay) or 0.1 ml Tris-HCI buffer (total mu
assay).
Vortex and pre-incubate in shaking water bath at 37°C for
5 min.
(iv) 0.1 ml DSLET (1 ILM) (mu 1 as-
say), 0.1 ml DAGO (1I1M) (total mu and mu 2 assays) or
0.1 ml DSLET (1 ltM) (delta assay).
Vortex and incubate in shaking water bath at 37'C for a
further 15 min.
Specific binding (i) 0.5 ml P2 (4mg ml-').
(ii) 0.1 ml 3H-DAGO (1.5 nM) (total mu
and mu 2 assays) or 0.1 ml 3H-DSLET (1.5 nM) (mu and
delta assays).
(iii) 0.1 ml Tris-HCl buffer (total mu as-
say), 0.1 ml DPDPE (20 nM) (mu 1 assay), 0.1 ml DSLET
(5 nM) (mu 2 assay) or 0.1 ml DAGO (5 nM) (delta assay).
Vortex and pre-incubate in shaking water bath at 37°C for
5 min.
(iv) 0.1 ml DSLET (mu 1 and delta as-
says), DAGO (total mu and mu 2 assays), morphine or M6G
standards at concentrations specified below, or 0.1 ml Tris-
HCl buffer.
Vortex and incubate in shaking water bath at 37°C for
15min.
Following the second incubation the procedure for all
assays was identical. The reaction was stopped by the addi-
tion of 5 ml ice cold Tris-HCl buffer to all tubes. The result-
ing solution was filtered through Whatman GF/B glass fibre
filters using a Baker 10 extraction system capable of filtering
ten samples simultaneously. The filter was washed twice with
5 ml of 10 mM Tris-HCl buffer and placed in scintillation
bottles with 5 ml scintillant fluid (Ecoscint, National Diag-
nostics). Four unused filter papers were impregnated with
0.1 ml of the relevant 3H-ligand and added to four similar
vials for the calculation of total counts. All vials are stored
for 48 h prior to counting in a Tri-care liquid scintillation
counter model 2425 (Hewlett Packard).
Standards For all assays blocking agent concentrations were
based on those suggested from studies of Yoburn et al.
(1988). The concentration range of opiate standards ranged
from zero, which gave 100% specific binding, to the concen-
tration required which inhibited all specific binding of 3H-
ligand to the opioid receptor (binding equivalent to the
NSB).
Validation procedures To confirm there was no biotransfor-
mation of morphine to M6G or vice-versa whilst incubation
was in progress, after incubation some tubes were assayed by
HPLC assessing morphine and M6G concentrations. In addi-
tion, to confirm the binding was actually at the opioid recep-
tor, all assays were performed in the presence or absence of
levorphanol (5pM) or its inactive stereoisomer dextrorphan
(5pM). In order to determine that the P2 was the optimal
fraction for use in the binding assays, all fractions produced
during tissue preparations (P1, SI, P2 and S2) were assessed
for opioid binding activity by their ability to bind the 3H-
DAGO ligand.
Calculation ofresults
The mean counts from the three or four tubes were cal-
culated prior to the calculation of binding.
The results are expressed as the percentage of specifically
bound 3H-ligand vs concentration of opioid.
Non-specific binding was defined as counts in the presence
of 1 fLM non-radioactive enkephalin ligand.
% Total bound =
counts of zero standard (std) - NSB
total counts
% Specific bound counts of zero std - NSB
(of total binding) = counts of zero std




From a plot of percentage 3H-ligand bound versus opiate
concentration an IC50 was ascertained and the ICsOs of cold
ligand (DAGO or DSLET), morphine and M6G compared
to determine relative binding affinities at each receptor.
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Statistical considerations
The IC50 was obtained from each assay and the mean ICms
of each compound compared for each receptor using the
Mann Whitney U test to determine if a statistically
significant difference in binding affinities was present. All
mean results are quoted with the standard error of the mean
(s.e.m.).
Results
Table II demonstrates the mean IC5os for morphine and
M6G obtained from a plot of % 3H-ligand bound versus
concentration of unlabelled ligand, morphine and M6G for
individual assays. Graphical representation of the results has
been achieved by plotting the means of % 3H-ligand bound
across all assays versus concentration in Figures 1 to 4.
There was no significant difference in affinity at the mu 1
receptor as identified with 3H-DSLET and unlabelled DA-
GO, with the mean IC50 of morphine and M6G being
300 nmol -1' and 211 nmol 1' respectively. Figure 1 demon-
strates that the affinity remained similar throughout the con-
centration range. Unlabelled DSLET bound with a higher
affinity than either compound as expected as this is the
enkephalin analogue defining this receptor.
At the mu 2 receptor, however, the mean IC5o of morphine
was 4.8 fold lower than that of M6G (17 nmol l' and
82 nmol 1' respectively) indicating a significantly increased
affinity (P = 0.01) for this receptor. Figure 2 demonstrates
this difference in affinity held for the whole concentration
range over which binding occurs.
The binding of morphine and M6G to the total mu (mu 1
and mu 2) was similar to that seen at the mu 2 receptor with
mean IC50s of 13 nmol 1' and 94 nmol 1' (P = 0.01) respec-
tively. Again this difference was maintained through out the
concentration range tested (Figure 3).
The initial results obtained in the delta receptor assay
showed considerable variability despite strict adherence to
experimental technique and hence a larger number of assays
were performed to ensure a reliable result. There was no
difference in binding affinities observed with the mean ICo of
morphine 365 nmol 1-1 and of M6G 305 nmol 1` (Figure 4).
There was no morphine or M6G found in the suspensions
incubating the alternative compound with the receptor tissue.
The results above are from experiments performed on
whole brain minus hypothalami. Therefore a single assay for
each receptor type was performed on P2 fractions of whole
rat brain homogenate to ensure the absence of hypothalamus
did not change the relative affinities of morphine and M6G.
The IC50s obtained are summarised in Table III. Similar IC50s
were obtained for both compounds at all mu receptors.
However, in the delta assay there appeared to be a significant
shift in IC_o for both compounds. However, the morphine:
M6G IC50 ratios were similar.
The presence of 5 jM levorphanol in the assays reduced the
competitive specific binding of the 3H-ligand to 0% in the
cases of the total mu and delta assays, to 1% in the mu 1
assay and to 28% in the case of the mu 2 assay. The inactive
isomer dextrorphan, used at an equal molar concentration,
resulted in a reduction of specific binding of 3H-ligand to
70% and 72% for the total mu and mu 2 assays respectively,
while in the cases of the mu 1 and delta assays no inhibition
was observed.
To obtain a sensitive radioreceptor assay it is necessary to
use the tissue fraction containing the highest concentration of
receptors with the least overall protein content as the non-
opioid protein will increase the non-specific binding of the
3H-ligand and hence reduce the sensitivity of the assay. Table
IV demonstrates the mean c.p.m. per 2 mg of protein for
each tissue fraction obtained during tissue preparation when
a total mu assay was performed. The pellet (P2) obtained
after ultracentrifugation was confirmed to have the largest
differential between specific and non-specific binding and













Figure 1 Mu 1 receptor binding. Graph of % specifically bound
3H-DSLET versus opiate concentration. x DSLET













Figure 2 Mu 2 receptor binding. Graph of % specifically bound
3H-DAGO versus opiate concentration. x DAGO (+ SEM);
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Figure 3 Total mu receptor binding. Graph of specifically bound
3H-DAGO versus opiate concentration. x DAGO (+ SEM);
-0- Morphine (+ SEM); -0- M6G (+ SEM).
Table II IC50 ofmorphine and morphine 6-glucuronide by receptor. The
ICo was defined as the drug concentration inhibiting 50% of specific
binding of the tritiated ligand
Receptor Morphine IC50 (nM) ± SEM M6G IC50 (nM) ± SEM
Total Mu 13±1 (n=5) 94±15 (n=5) P=0.01
Mu 1 300 ±93 (n = 7) 211 ± 20 (n = 6) NS
Mu2 17±2 (n=5) 82±11(n=7)P=0.01
Delta 365 ±40 (n = 13) 305 ±37 (n = 11) NS
w
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Figure 4 Delta receptor binding. Graph of specifically bound
3H-DSLET versus opiate concentration. - x - DSLET (+ SEM);
0- Morphine (+ SEM); -*- M6G (+ SEM).
Table III IC50 ofmorphineandmorphine6-glucuronide byreceptorin
whole brain preparations
Morphine IC50 M6G ICs0
Receptor (nM) (nM)
Total mu 7 80




The current study has demonstrated that M6G has a 4- to
5-fold lower binding affinity for the mu 2 opioid receptor in
comparison with morphine, and is concordant with the
recent observations of Paul et al. (1989). As it is the mu 2
receptor which is thought to be responsible for principally
mediating the lethal effects of morphine (Wolozin & Paster-
nak, 1981), particularly respiratory depression (Ling et al.,
1983; Ling et al., 1985), this study provides a possible explan-
ation for the significantly lower degree of respiratory depres-
sion, nausea and vomiting and sedation observed in man
after M6G than after morphine (Thompson et al., 1990). The
difference in binding affinity also takes on more significance
when considering the observation that M6G has approx-
imately three times the systemic analgesic potency of mor-
phine (Shimomura et al., 1971; Pasternak et al., 1987; Abbot
& Palmour, 1988, Thompson et al., 1990). Despite this
marked reduction in binding affinity for the mu 2 receptor
M6G undoubtedly still causes respiratory depression when
plasma concentrations are high (Hasselstrom et al., 1989;
Osborne et al., 1986). This is particularly observed in patients
with renal failure administered morphine as the major excre-
tion route of M6G is renal. The respiratory depression seen
in this situation may be not only due to the high plasma
concentrations of M6G binding to the mu2 receptor, but
possibly also due to binding to the delta receptor which has
also been suggested to play a role in mediating respiratory
depression (Morin-Surun et al., 1984; Pazos & Florez, 1983;
Pazos & Florez, 1984).
The 4- to 5-fold higher affinity of morphine for the mu 2
receptor was also seen over the total mu receptor population.
This is not surprising as approximately 70% of mu receptors
are mu 2 receptors (Chang & Cuatrecasas, 1979; Wolozin &
Pasternak, 1981) and hence binding to the total mu receptor
population is essentially a reflection of binding to the mu 2
receptor. This observation is also similar to that ofPaul et al.
(1989).
Oguri et al. (1987) found M6G had a slightly higher
affinity for the delta receptor as labelled by the relatively
poorly selective 3H-leucine enkephalin. A similar trend was
observed in the current study with the IC5o of morphine and
M6G being 365 nM and 305 nM respectively. However the
difference was not statistically different.
Supraspinal analgesia is primarily mediated by the mu 1
receptor (Wolozin & Pasternak, 1981; Pasternak et al., 1986).
M6G has a 3-fold systemic analgesic potency advantage over
morphine and a substantial 50- 200-fold potency advantage
when administered directly into the cerebral ventricles (Shim-
omura et al., 1971; Abbott & Palmour, 1988) and hence an
increased affinity of M6G for this receptor might reasonably
be expected. However there was no significant difference in
binding affinity seen at the mu 1 receptor in this study with
IC50s of 300 nM and 211 nM for morphine and M6G respec-
tively. The only other study to examine the affinities of
morphine and M6G at the mu 1 receptor using a different
3H-ligand ([D-ala2, D-leu5]enkephalin or DADLE) found a
slightly increased affinity of morphine for the mu 1 receptor
(Paul et al., 1989). There are several reasons why this appar-
ent inconsistency may exist. Firstly and most importantly,
radiolabelled affinity studies only reflect the binding of a
compound to a receptor, not activation of that receptor to
produce a physiological response. Hence there may be
differences in intrinsic activity of morphine and M6G at the
receptor once bound. These differences may result in differing
activation of the second messenger system, or differences in
the allosteric modulation of nearby delta receptors possibly
existing in an 'opioid receptor complex' in the opioid recep-
tor model described by Rothman et al. (1982). It is now
realised the delta receptor plays a larger role in mediating
supraspinal analgesia than was first thought although it is
likely this role is mainly modulatory (Heyman et al., 1988;
Heyman et al., 1989; Mathiasen et al., 1987).
Secondly, the kappa receptor may also have a minor role
in mediating supraspinal analgesia (Millan et al., 1989) and
the affinity of M6G for the kappa receptor has not yet been
accurately determined although is thought to be low (Paster-
nak et al., 1987). Thirdly, binding studies are carried out in
particular physiological conditions which can only approx-
imate the situation in vivo. Further study of the interactions
of M6G and morphine with opioid receptors at a molecular
level is clearly required.
In conclusion, this study has demonstrated a significantly
lower affinity of M6G in comparison to morphine for the
mu 2 opioid receptor, the receptor postulated to be the prin-
cipal mediator of the respiratory depression and gastro-
intestinal effects of morphine. It hence offers one possible
explanation for the observation that M6G induces less res-
piratory depression and vomiting than equipotent doses of
morphine in man. However, the marked analgesic potency of
M6G over morphine remains unexplained and further study
into the molecular interactions of M6G and opioid receptors
and investigation of the second messenger system is clearly
required.
Table IV Total mu receptor binding in different rat brain homogenate fractions
(counts/min1l 2 mg ' protein)
Homogenate
fraction Total bound Non-specific bound Specific bound
Crude homogenate 776 273 553
Ist pellet (P1) 758 240 518
1st supernatant (SI) 209 104 165
2nd pellet (P2) 1136 353 783
2nd supernatant (S2) 53 59 -6126 D. HUCKS et al.
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